EUVIMEDEUVIMED entdecken
Crossref

Understanding the upper bound of survival for conducting and critically appraising economic evaluations of low-risk cancers

Xuanqian Xie iD, Ishita Joshi, Myra Wang, Chunmei Li

Expert Review of Pharmacoeconomics & Outcomes Research · 2025

DOI: 10.1080/14737167.2025.2522326 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2025. Verfasst von Xuanqian Xie und 3 weiteren Autor:innen. Beteiligte Einrichtung: Acute and Hospital-Based Care, Ontario Health, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Quality-Adjusted Life Years, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: In most developed countries, overall survival rates for low-risk cancers (e.g. localized prostate and thyroid cancer) are comparable to those of the general population. The general population's survival rate may serve as an upper bound for survival in people with these cancers. METHODS: By applying this concept, we demonstrated limitations of using Markov models for low-risk cancers and proposed an alternative modeling approach. RESULTS: Markov disease progression models typically depict a gradual progression from early to advanced cancer stages and an increasing risk of cancer-specific mortality over time. However, data showed that the risk of death from cancer was often the greatest within the first few years following diagnosis. We therefore proposed an alternative modeling approach. This method involves calculating the average quality-adjusted life-years (QALYs) from the integrals of the survival curve, multiplied by the corresponding health utility curve. Alternatively, QALYs may be estimated by averaging survival and utility within each time interval and summing these estimates across intervals. We also applied these concepts to the critical appraisal of published economic evaluations. CONCLUSIONS: Understanding the upper bound of survival for low-risk cancers enables health economists to more accurately conduct cost-effectiveness analyses and assess the credibility of published economic evaluations. [Figure: see text].

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality-Adjusted Life YearsNeoplasmsHumansCost-Benefit AnalysisMarkov ChainsSurvival RateDisease ProgressionMaleTime FactorsProstatic NeoplasmsNeoplasm StagingDeveloped Countries

Stichwörter der Autor:innen

Low-risk cancerQALYhealth utilitymodelingrelative survival ratio

Autor:innen und Institutionen

  • Acute and Hospital-Based Care, Ontario Health, Toronto, ON, Canada.

ORCID-Profile: Xuanqian Xie

Zitieren

APA

Xie, X., Joshi, I., Wang, M., & Li, C. (2025). Understanding the upper bound of survival for conducting and critically appraising economic evaluations of low-risk cancers. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2025.2522326

Vancouver

Xie X, Joshi I, Wang M, Li C. Understanding the upper bound of survival for conducting and critically appraising economic evaluations of low-risk cancers. Expert Review of Pharmacoeconomics & Outcomes Research. 2025. doi:10.1080/14737167.2025.2522326

BibTeX
@article{Xie2025,
  author = {Xie, Xuanqian and Joshi, Ishita and Wang, Myra and Li, Chunmei},
  title = {Understanding the upper bound of survival for conducting and critically appraising economic evaluations of low-risk cancers},
  journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
  year = {2025},
  doi = {10.1080/14737167.2025.2522326}
}
Kostenlos starten →